In addition, our results showed that treatment with siRNA against FBP1 downregulated FBP1 expression and consequently promoted the cell proliferation and cell invasiveness and enhanced glycolysis flux in cancer cells, suggesting that FBP1 expression can be considered as an antitumor molecular target in lung cancer. This evidence concerns the gene FBP1 and cancer.